Johnson and Johnson's Covid-19 vaccine generates 'promising' immune response
Johnson&Johnson's Covid-19 vaccine generated a 'promising' immune response, results from from phase one and two clinical trials showed.
Most of the volunteers taking part in the trials showed detectable neutralising antibodies 28 days after being administered the shot.
By day 57 all volunteers, with ages ranging from 18 to those 65 or older, had detectable antibodies, regardless of whether they were given a low or high dose of the vaccine.
Among those aged 18 to 55, the level of antibodies had remained stable for at least 71 days.
The data, which was published in the New England Journal of Medicine, also showed that the vaccine was safe.
In remarks to CNBC, J&J's Chief Scientific Officer, Paul Stoffels, said the readings from the trial gave his company "confidence" that the vaccine would prove highly effective in countering the virus.
According to CNBC, results from the ongoing 45,000-person phase three trial were expected later in January.
Important Legal Notice about News Sources: Pilling and Co Stockbrokers Ltd. is not responsible for the content or accuracy of third party news articles and we may not share the views of the author. We provide third party news for your convenience and information only and make no representation or endorsement whatsoever and hereby exclude all liability for any loss or damage that may be incurred by you as a result of your access or use. Please note that third party content may be subject to terms and conditions imposed by the third party owner of that content.